The University of Chicago Header Logo

Connection

Mark Lingen to Carcinoma, Squamous Cell

This is a "connection" page, showing publications Mark Lingen has written about Carcinoma, Squamous Cell.
Connection Strength

7.259
  1. Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Oral Cavity Dysplasia: Why Does Histologic Grading Continue to be Contentious? Head Neck Pathol. 2023 Jun; 17(2):292-298.
    View in: PubMed
    Score: 0.498
  2. Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association. J Am Dent Assoc. 2017 11; 148(11):797-813.e52.
    View in: PubMed
    Score: 0.339
  3. CD34 and a smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Apr; 117(4):477-82.
    View in: PubMed
    Score: 0.260
  4. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013 Jan; 49(1):1-8.
    View in: PubMed
    Score: 0.236
  5. Brush-based cytology screening in the tonsils and cervix: there is a difference! Cancer Prev Res (Phila). 2011 Sep; 4(9):1350-2.
    View in: PubMed
    Score: 0.221
  6. Assuring dental student head and neck cancer screening competency. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar; 111(3):267-8.
    View in: PubMed
    Score: 0.214
  7. Can saliva-based HPV tests establish cancer risk and guide patient management? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep; 110(3):273-4.
    View in: PubMed
    Score: 0.206
  8. Screening for oral premalignancy and cancer: what platform and which biomarkers? Cancer Prev Res (Phila). 2010 Sep; 3(9):1056-9.
    View in: PubMed
    Score: 0.206
  9. Pragmatics versus contrarians: how does one resolve their differences with respect to oral cancer screening? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar; 109(3):325-6.
    View in: PubMed
    Score: 0.199
  10. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila). 2009 Apr; 2(4):385-93.
    View in: PubMed
    Score: 0.187
  11. Tissue microarray - a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med. 2008 Mar; 37(3):166-76.
    View in: PubMed
    Score: 0.174
  12. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008 Apr; 88(4):342-53.
    View in: PubMed
    Score: 0.173
  13. Head and neck cancer: the pursuit of molecular diagnostic markers. Semin Oncol. 2004 Dec; 31(6):718-25.
    View in: PubMed
    Score: 0.139
  14. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 2003 Feb 01; 63(3):555-9.
    View in: PubMed
    Score: 0.122
  15. Classification and identification of genes associated with oral cancer based on gene expression profiles. A preliminary study. N Y State Dent J. 2003 Feb; 69(2):23-6.
    View in: PubMed
    Score: 0.122
  16. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
    View in: PubMed
    Score: 0.118
  17. Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma. Int J Cancer. 2002 Jul 20; 100(3):283-9.
    View in: PubMed
    Score: 0.118
  18. Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev. 2021 12 10; 12:CD010173.
    View in: PubMed
    Score: 0.113
  19. Angiogenesis in oral cancer. J Dent Educ. 2001 Nov; 65(11):1282-90.
    View in: PubMed
    Score: 0.112
  20. Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2021 09 21; 2(9):100399.
    View in: PubMed
    Score: 0.111
  21. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001 Sep; 93(6):781-5.
    View in: PubMed
    Score: 0.111
  22. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2021 07 20; 7:CD010276.
    View in: PubMed
    Score: 0.110
  23. Squamous cell carcinoma of the head and neck in nonsmokers: clinical and biologic characteristics and implications for management. Curr Opin Oncol. 2001 May; 13(3):176-82.
    View in: PubMed
    Score: 0.108
  24. Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer. 2021 05 15; 127(10):1576-1589.
    View in: PubMed
    Score: 0.105
  25. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin Investig Drugs. 2000 Dec; 9(12):2855-72.
    View in: PubMed
    Score: 0.105
  26. Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck. 2000 Jul; 22(4):328-35.
    View in: PubMed
    Score: 0.102
  27. Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful? Head Neck Pathol. 2020 Dec; 14(4):966-973.
    View in: PubMed
    Score: 0.101
  28. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.093
  29. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med. 1999; 10(2):153-64.
    View in: PubMed
    Score: 0.092
  30. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998 Dec 01; 58(23):5551-8.
    View in: PubMed
    Score: 0.091
  31. Understanding the biology of oral cancer and chemoprevention. CDS Rev. 1998 May-Jun; 91(4):24-8.
    View in: PubMed
    Score: 0.088
  32. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 06; 125(6):650-669.
    View in: PubMed
    Score: 0.087
  33. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc. 2017 10; 148(10):712-727.e10.
    View in: PubMed
    Score: 0.084
  34. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907.
    View in: PubMed
    Score: 0.082
  35. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.081
  36. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538.
    View in: PubMed
    Score: 0.077
  37. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol. 1996 Jul; 149(1):247-58.
    View in: PubMed
    Score: 0.077
  38. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.077
  39. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC. Oncotarget. 2016 Mar 22; 7(12):14029-47.
    View in: PubMed
    Score: 0.076
  40. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest. 1996 Feb; 74(2):476-83.
    View in: PubMed
    Score: 0.075
  41. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2015 May 29; (5):CD010276.
    View in: PubMed
    Score: 0.072
  42. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
    View in: PubMed
    Score: 0.071
  43. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
    View in: PubMed
    Score: 0.069
  44. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6.
    View in: PubMed
    Score: 0.069
  45. WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Mol Cancer Res. 2015 Feb; 13(2):293-304.
    View in: PubMed
    Score: 0.069
  46. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8.
    View in: PubMed
    Score: 0.068
  47. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.068
  48. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014; 9(3):e90171.
    View in: PubMed
    Score: 0.066
  49. Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis. 2014 Apr; 20(3):e76-80.
    View in: PubMed
    Score: 0.063
  50. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013 May; 15(5):461-71.
    View in: PubMed
    Score: 0.062
  51. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.060
  52. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012 Jul; 36(7):945-54.
    View in: PubMed
    Score: 0.059
  53. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. Tex Dent J. 2012 May; 129(5):491-507.
    View in: PubMed
    Score: 0.058
  54. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.057
  55. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):664-72.
    View in: PubMed
    Score: 0.057
  56. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis. 2011 Apr; 17 Suppl 1:7-22.
    View in: PubMed
    Score: 0.054
  57. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
    View in: PubMed
    Score: 0.054
  58. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011 Feb; 4(2):230-7.
    View in: PubMed
    Score: 0.053
  59. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010 May; 141(5):509-20.
    View in: PubMed
    Score: 0.050
  60. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.047
  61. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74.
    View in: PubMed
    Score: 0.046
  62. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007 Oct 15; 67(20):9685-93.
    View in: PubMed
    Score: 0.042
  63. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303.
    View in: PubMed
    Score: 0.039
  64. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
    View in: PubMed
    Score: 0.037
  65. Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol. 2004 Nov; 40(10):1040-7.
    View in: PubMed
    Score: 0.034
  66. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
    View in: PubMed
    Score: 0.033
  67. Gene expression levels in different stages of progression in oral squamous cell carcinoma. Proc AMIA Symp. 2002; 415-9.
    View in: PubMed
    Score: 0.028
  68. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999 Aug; 108(8):781-7.
    View in: PubMed
    Score: 0.024
  69. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
    View in: PubMed
    Score: 0.022
  70. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.015
  71. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
    View in: PubMed
    Score: 0.012
  72. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010 Mar; 17(3):499-512.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.